Aegera Therapeutics, Inc.

New data for Celgene Corp. ’s BTK inhibitor CC-292 have shown higher response rates in chronic lymphocytic leukemia than previously reported, building expectations for the product – but Pharmacyc

Mergers & Acquisitions

A week after successfully winning US approval of its lupus drug Benlysta (belimumab), Human Genome Sciences is stepping up its game in the cancer therapy arena by adding a new asset to its development

Aegera Therapeutics has raised Cdn$7 million ($6.4 million) through a debt facility provided by Investissement Québec. The Canadian company will use the cash to fund its two lead programmes, both of w